NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 5, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

September 28, 2022

Conditions

Multiple Myeloma

Interventions

DRUG

Isatuximab SAR650984

Pharmaceutical form: solution Route of administration: intravenous

Trial Locations (13)

Investigational Site Number :392001, Nagoya

Investigational Site Number :392005, Shibukawa-shi

Investigational Site Number :392010, Hiroshima

Investigational Site Number :392015, Kanazawa

Investigational Site Number :392016, Kyoto

Investigational Site Number :392008, Suwa-shi

Investigational Site Number :392003, Okayama

Investigational Site Number :392009, Osaka

Investigational Site Number :392013, Suita-shi

Investigational Site Number :392017, Sunto-gun

Investigational Site Number :392012, Chuo-ku

Investigational Site Number :392002, Shibuya-ku

Investigational Site Number :392011, Yamagata